Ms Tornsen will be responsible for all US based operations and will report to the CEO.
Maria Tornsen has broad commercial leadership experience having spent more than 20 years in the biopharma industry in senior commercial roles. Most recently Ms Tornsen held the position of Chief Commercial Officer at
'We are pleased to welcome Ms Tornsen to the executive management team as President of our US operations. She brings invaluable experience from building commercial organisations, driving growth and profitability in the area of rare diseases, which will be critical as we target the next step in our development.' said CEO
'I am delighted to join Calliditas at this exciting time in the company's history, with the recent full FDA approval of TARPEYO and an innovative late-stage pipeline in rare diseases. I look forward to working with the Calliditas team to continue advancing the TARPEYO launch and develop our capabilities to support further growth.' said Maria Tornsen.
Calliditas received full FDA approval of TARPEYO(budesonide) delayed release capsules, a targeted treatment to reduce the loss of kidney function in patients with primary IgA nephropathy (IgAN) at risk of disease progression on
Contact:
Tel: +46 76 403 35 43
Email: asa.hillsten@calliditas.com
About Calliditas
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the development of Calliditas' pipeline. The words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'target,' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties, and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, any related to Calliditas' business, operations, clinical trials, intellectual property of the NEFECON franchise globally, competition from other companies, pipeline development, revenue and product sales projections or forecasts and other risks identified in the section entitled 'Risk Factors' in Calliditas' reports filed with the
Contact:
Tel: +1 844-442-0011
Email: medical.information@calliditas.com
(C) 2024 Electronic News Publishing, source